Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,016
- 试验地点
- 1
- 主要终点
- Overall mortality
研究概览
简要总结
The present study includes patients with tricuspid regurgitation and heart failure diagnosed with echocardiography. The aim is to evaluate the physical performance of patients with tricuspid regurgitation and heart failure, to observe the course of the diseases and to allow a better understanding of new therapy options.
详细描述
Moderate to severe tricuspid regurgitation (TR) is a frequent result of left heart failure causing a limiting prognosis. The new interventional therapies have given more relevance to the questions of the prognostic significance of severe TR in the various heart failure entities.
Important but currently unanswered questions for the establishment of successful, interventional therapies of TR are:
- What effect does TR have on patients with heart failure?
- Which patients at which stage of the disease benefit from interventional TR-therapies? In order to answer these questions, the aim of the study is to prospectively record the prevalence of TR (including quantification) in all heart failure patients at the Charité, followed by long-term observation to assess its prognostic relevance.
In addition to answering the above-mentioned questions, the project will allow a central registration of all symptomatic heart failure patients. A comparative outcome analysis per propensity score matching with the untreated patients of the registry would allow to give first considerations which patients are ideal candidates for interventional therapies.
Primary endpoint: death Secondary endpoint: hospitalization due to cardiac decompensation, exercise capacity according to NYHA classification
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with transthoracic echocardiography (TTE) and heart failure
- •Reported heart failure symptoms within the last two years
- •>18 years
- •Written, documented consent
排除标准
- •Patients in care or unable to consent
结局指标
主要结局
Overall mortality
时间窗: 24 months after enrolment
Overall mortality after 24 months (number of deceased patients)
次要结局
- hospitalization due to cardiac decompensation(24 months after enrolment)
- exercise capacity according to NYHA classification(24 months after enrolment)
研究者
Prof. Dr. Henryk Dreger
Professor
Charite University, Berlin, Germany